In summary, we show here that pharmacological inhibition of the Bruton Tyrosine Kinase does not prevent renal injury and instead increases renal fibrosis after UUO- and rhabdomyolysis suggesting that ibrutinib should not be considered a candidate drug for patients developing AKI or in transition from AKI to CKD. This evidence concerns the gene BTK and rhabdomyolysis.